This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for May 6, 2020
by Zacks Equity Research
Companies in the news are: LITE, ITW, INCY, PTLA
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
Incyte (INCY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Remdesivir Gets Emergency Approval: What's In Store for Gilead?
by Zacks Equity Research
In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?
Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.
Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Novartis (NVS) reports strong results for the first quarter, driven by solid performance from key drugs and forward purchasing due to COVID-19.
Focus on Coronavirus Treatments to Boost Biotech Stocks
by Zacks Equity Research
With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.
Factors Setting the Tone for Novartis' (NVS) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with the impact of the coronavirus pandemic on its outlook when Novartis (NVS) reports first-quarter 2020 results.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Alexion to Evaluate Rare Disease Drug for COVID-19, Shares Up
by Zacks Equity Research
Alexion (ALXN) gains as it announces plans to initiate a study to evaluate Ultomiris for the COVID-19 infection.
Roche's Ocrevus Line Extension Application Moves Forward
by Zacks Equity Research
Roche's (RHHBY) regulatory applications seeking approval for shorter infusion time for administration of multiple sclerosis drug, Ocrevus, move forward in the United States and Europe.
Novartis To Initiate Hydroxychloroquine Study for Coronavirus
by Zacks Equity Research
Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre
by Zacks Equity Research
Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.
Roche's New Test to Detect Antibodies to Fight Coronavirus
by Zacks Equity Research
Roche (RHHBY) develops Elecsys, a new serology test, for the detection of antibodies against SARS-CoV-2, the virus causing COVID-19. The company plans to launch the same early next month.
Gilead's (GILD) Coronavirus Drug Shows Promise, Shares Gain
by Zacks Equity Research
Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
by Zacks Equity Research
Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
10 Stocks Leading the Rally in the S&P 500 ETF
by Sweta Killa
Signs of a slowdown in the number of hospitalizations and intensive-care admissions in New York and Europe has led to optimism over the reopening of the economy soon and improving activity in the near future.
Bausch (BHC) Starts Study on Virazole for Coronavirus Infection
by Zacks Equity Research
Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.